



The Detection of Mupirocin Resistance and Nasal Carriage of Methicillin Resistant *Staphylococcus aureus* among Healthcare Workers at University Hospitals of Tehran, Iran

Solmaz OHADIAN MOGHADAM¹, *Mohammad Reza POURMAND^{1,2}, Abolfazl DA-VOODABADI¹

1. Dept. of Pathobiology, School of Public Health, Tebran University of Medical Sciences, Tebran, Iran
2. Biotechnology Research Center, Tebran University of Medical Sciences, Tebran, Iran

*Corresponding Author: Email: mpourmand@tums.ac.ir

(Received 13 Oct 2014; accepted 21 Jan 2015)

Abstract

Background: Nasal mupirocin is found to eradicate effectively methicillin-resistant *Staphylococcus aureus* (MRSA) from colonized patients, but there are concerns about resistant strains. The aim of this study was to detect the mupirocin resistance and nasal carriage of methicillin resistant *S. aureus* among healthcare workers (HCWS) at the university hospitals of Tehran.

Methods: Totally 270 nasal swabs were collected and *S. aureus* were identified by confirmatory tests in 2013. Determination of oxacillin and mupirocin resistance was performed by disk diffusion method and the mupirocin MIC assessed using E-test. The *ileS-2* (*mupA*) and *mecA* genes were detected in DNA extracts by multiplex PCR.

Results: The prevalence of *S. aureus* nasal carriage among HCWs was 14.44%. E-test and disk diffusion methods showed 5 and 4 mupirocin resistant isolates, respectively. Statistically significant difference was observed between sex ($P=0.035$), hospitals ($P=0.0001$) and occupation ($P=0.009$) with nasal carriage of *S. aureus*. A significant difference was found between sex ($P=0.041$) and occupation (0.034) with regard to MRSA carriage. All MRSA isolates were susceptible to linezolid, fusidic acid and vancomycin.

Conclusion: Since the HCWs play an important role as a reservoir for resistant isolates in the hospital setting, regularly screening should be performed for identification of nasal carriers.

Keywords: Methicillin-resistant *Staphylococcus aureus*, Mupirocin, Healthcare workers, Nasal carriers

Introduction

The global emergence of methicillin-resistant *Staphylococcus aureus* (MRSA) has become a thoughtful problem for public health. MRSA has been identified as one of the major cause of nosocomial infections, which is resistant to various classes of antibiotics (1). Staphylococci could colonize the skin and nasal mucosa (2).

Eradication or inhibition of staphylococcal colonization is still considered as an important strategy to prevent infection and transmission of these

strains. Rationale behind such a strategy is that the most staphylococcal infections are caused by endogenous strains; so, carriage of *S. aureus* is a major risk factor for subsequent infections (3). The eradication of this organism in nasal carriers with mupirocin has been shown to reduce the rate of nosocomial infections in hospitalized patients (4).

Mupirocin is available as an antimicrobial agent. Nasal formulation of mupirocin was recommended by the Food and Drug Administration of

United States (US FDA) as part of an infection control for using in the eradication of nasal carriage of *S. aureus* in adult patients and healthcare workers (HCW) to reduce the risk of infection among high-risk patients for acquisition of MRSA. Using mupirocin is limited for infection control and other prophylactic functions in order to tackle the concerns of the emergence of resistance (5).

There are three groups of susceptibility to mupirocin that include susceptible to mupirocin ($MIC \leq 4 \mu\text{g/ml}$), low level resistant to mupirocin (MIC to $64 \mu\text{g/ml}$) and high level resistant to mupirocin ($MIC \geq 512 \mu\text{g/ml}$) (6). Currently there is no desirable method for interpreting the susceptibility tests of mupirocin. Existing methods based on MIC determination by E-test method and detection of resistance genes by PCR are used (5). Since HCWs are in direct contact by the patients, they have a significant role in dissemination of resistant isolates in the hospital setting.

Therefore, we decided to do present study in order to evaluate the prevalence of MRSA that are resistant to mupirocin, isolated from HCWs nasal carriers and accomplish molecular techniques and the MIC together for epidemiological purposes. Antibiotic susceptibility pattern of MSSA and MRSA isolates was determined as well. If nasal carriers identified, the therapeutic measures can be proceed to prevent the dispersion of resistant isolates in hospital setting.

Materials and Methods

Study design

In this cross sectional survey 270 HCWs nasal swabs were collected from five hospitals affiliated to Tehran University of Medical Sciences (TUMS) in 2013. All participants gave written informed consent.

Bacterial isolation

After sampling, using sterile swabs, samples immediately transferred to transport medium moved to the Department of Pathobiology, then sub cultured on blood agar and incubated for 24 hours at 37 °C. Identification of *S. aureus* was performed by confirmatory tests [Gram's stain, catalase, coagu-

lase and DNase tests and mannitol fermentation on mannitol salt agar (MSA)].

Antibiotic susceptibility tests

Disk diffusion method

The antibiotic susceptibility pattern was determined by the disk diffusion method. The antibiotics used in this study included: amikacin (30 μg), ciprofloxacin (5 μg), erythromycin (30 μg), fusidic acid (5 μg), gentamicin (10 μg) linezolid (30 μg), mupirocin (5 μg), oxacillin (1 μg), rifampin (5 μg), tetracycline (30 μg), tobramycin (10 μg) and vancomycin (30 μg). (MAST Diagnostics, Merseyside, U.K.). This was carried out on Mueller-Hinton agar medium (for oxacillin containing 4% NaCl) and growth inhibition zones were measured and interpreted according to the CLSI guidelines (7). *S. aureus* ATCC29213 was used as control strain.

Determination of minimal inhibitory concentration (MIC)

The mupirocin MIC assessed using E-test® mupirocin strips (AB Biodisk, Solna, Sweden) according to the manufacture's guidelines. Strains were considered susceptible if MIC was $\leq 4 \text{ mg/l}$ and levels of mupirocin resistance were defined as low-level with MIC 8–256 mg/l and high-level with MIC $\geq 512 \text{ mg/l}$.

DNA extraction

DNA was extracted using a DNeasy kit (Qiagen, Valencia, CA) as recommended by the manufacturer.

Multiplex PCR

The *ileS-2* (*mupA* gene) and *mecA* genes were detected in DNA extracts by multiplex PCR assay, as described previously (8) with some modifications (Table 1). The genes were amplified on an Eppendorf (Hamburg, Germany) thermocycler with the final volume of 50 μlit containing 24 μlit of Qiagen HotStarTaq master mix (Invitrogen, Carlsbad, CA, contain PCR buffer with 3 mM MgCl_2 , 400 μM of each dNTP and 2.5 units HotStarTaq DNA Polymerase), 2 μlit of each primer (20 pMol, *MecA* and *Mup*), 14 μlit of RNase-free water and 8 μlit of DNA template. Then products were elec-

trophoresed on agarose gel and the presence or absence of resulting bands was evaluated.

Statistical analysis

Data were analyzed using SPSS statistical software, version 16.0. The categorical data were compared

using the Chi-square test or Fisher's exact test and quantitative variables were compared by one-way ANOVA. Statistical significance was set at 0.05 levels.

Table 1: Multiplex PCR condition and primers used in this study

Gene	Primers	Relevant produced product	positive control	Negative control	Amplification condition
<i>mecA</i>	MecA1 (5'- GTA GAA ATG ACT GAA CGT CCG ATA A-3') MecA2 (5'-CCA ATT CCA CAT TGT TTC GGT CTAA-3')	310 bp	Oxacillin-resistant <i>S. aureus</i> ATCC 33591	Oxacillin-susceptible <i>S. aureus</i> ATCC 25923	Initial denaturation: 94°C, 5 min 35 amplification cycles: denaturation :94°C, 35 s annealing: 58°C, 30 s elongation:72°C, 45 s final elongation:72°C, 10 min
<i>ileS-2</i> (<i>mupA</i> gene)	MupA (5'-TAT ATT ATGCGA TGG AAG GTT GG-3') MupB (5'-AAT AAAATC AGC TGG AAA GTG TTG-3')	456 bp	Mupirocin-resistant <i>S. aureus</i> HU1A	Mupirocin-susceptible <i>S. aureus</i> HU9A	

Results

Totally 270 nasal swabs were taken from HCWs (including physicians, nurses, paramedical staff and crewmembers). The mean age of HCWs was 34.21 years (range from 21 to 53 years) and male to female ratio of 0.481(183 female and 87 male).

Of 270 samples, 39 *S. aureus* (14.44%) were isolated, among which 17 (43.58%) were resistant to methicillin (Table 2). All these strains were isolated from A, B and C hospitals and there was no *S. aureus* nasal carrier among HCWs of D and E hospitals. Demographic characteristics of the nasal carriers of *S. aureus* are summarized in Table 3.

Table 2: Characteristics of collected specimens

Hospitals	n(%) of collected swabs	n(%) of isolated <i>S. aureus</i>	n(%) of isolated methicillin-resistant <i>S. aureus</i> (MRSA)	n(%) of isolated mupirocin-resistant <i>S. aureus</i> (MuRSA)
A	35(12.97)	14(35.9)	7(41.18)	2(40)
B	43(15.92)	11(28.2)	3(17.64)	1(20)
C	79(29.27)	14(35.9)	7(41.18)	2(40)
D	70(25.92)	0	0	0
E	43(15.92)	0	0	0
Total	270(100)	39(100)	17(100)	5(100)

Table 3: Demographic characteristics of *S. aureus* nasal carriers

Characteristics	Mean Age (Year)	Work Experience Mean (Year)	Sex (No.)		Designation
			F	M	
C	30	6	7	7	physician:2/Paramedical staff:3/Nurse:8 crew members:1
B	37	11	7	4	Physicien:2/Paramedical staff:2/Nurse:5 crew members:2

A	38	12	7	7	Physicien:2/Paramedical staff:1/Nurse:8 crew members:3
---	----	----	---	---	---

Using E-test method, 5 isolates were identified as mupirocin resistant *S. aureus* (MuRSA), while disk diffusion method showed four MuRSA. Multiplex PCR assay results showed that two *S. aureus* were positive for *mupA* gene and both of them showed high level resistance to mupirocin (MIC>1024). All MRSA isolates were positive for *mecA* gene. MIC range for all strains studied for mupirocin resistance was between < 4 and >

1024 (Table 4). Furthermore, it is notable that all mupirocin resistant isolates were MRSA and there were no MuRSA among methicillin susceptible *S. aureus* (MSSA). The frequencies of MRSA, MSSA and MuRSA isolates were different (Table 2). Significant difference was observed between the hospitals under studied with nasal carriage of *S. aureus* (Table 5).

Table 4: Characteristics of mupirocin-resistant *S. aureus* isolates

Isolate	<i>mecA/mupA</i>	Susceptibility to mupirocin by disk diffusion method	Mupirocin MIC(μ g/ml)
S2	+/-	R	24
S9	+/-	R	>1024
M9	+/-	R	24
SH4	+/+	S	>1024
SH10	+/+	R	>1024

Table 5: Statistical analysis for nasal carriage of *S. aureus* among HCWs

Variable	Nasal carrier (n=39)		P-Value		Odds ratio					
	MSSA, No. (%)	MRSA, No. (%)	<i>S. aureus</i> carrier status	MRSA carrier status	Upper		95% Confidence Interval		Value	
	(n=22)	(n=17)			<i>S. aureus</i>	MRSA	<i>S. aureus</i>	MRSA	<i>S. aureus</i> ¹⁾	MRSA ²⁾
Hospital										
A	7(31.8)	7(41.18)	(P=0.000)	(P=0.436)						
B	8(36.4)	3(17.64)								
C	7(31.8)	7(41.18)								
D	0	0								
E	0	0								
Sex			(P=0.035)	(P=0.041)	4.660	0.972	1.046	0.067	2.208	0.255
Female	15(68.2)	6(35.3)								
Male	7(31.8)	11(64.7)								
Age(years)										
<30	6(27.28)	9(52.94)	(P=0.285)	(P=0.142)						
30-40	8(36.36)	6(35.3)								
>40	8(36.36)	2(11.76)								
Years of Working			(P=0.437)	(P=0.103)						
0-9	9(40.9)	12(70.6)								
9-15	4(18.2)	3(17.64)								
15-29	9(40.9)	2(11.76)								
Occupation										
Nurse	8(36.36)	12(70.6)	(P=0.009)	(P=0.034)						
paramedical staff	6(27.27)	0								
crew member	6(27.27)	2(11.76)								
Physician	2(9.1)	3(17.64)								

¹⁾: Odds Ratio for *S. aureus* nasal colonization (Negative / Positive)

²⁾: Odds Ratio for MRSA nasal colonization (Negative / Positive)

There was no significant difference between the age and years of working in hospital with regard to nasal carriage of MSSA, MRSA and MuRSA. But statistically significant difference was observed between nursing occupation with nasal carriage of MSSA, MRSA but not with MuRSA (Table 5 and 6). A significant relation was observed

between the sexes with regard to the nasal carriage of *S. aureus* ($P=0.035$) and MRSA ($P=0.041$). All MSSA and MRSA strains were susceptible to linezolid, fusidic acid and vancomycin. Antibiotic susceptibility pattern of MRSA and MSSA isolates is presented in Table 7.

Table 6: Statistical analysis for nasal carriage of MuRSA among HCWs

Variable	Nasal carrier (n=39)		P-value	Odds ratio		
	MuSSA No. (%) (n=34)	MuRSA No. (%) (n=5)		95% Confidence Interval Upper Lower Value ¹⁾		
Age			P value > 0.05 ($P=0.950$)			
<30	13(38.23)	2(40)				
30-40	12(35.30)	2(40)				
>40	9(26.47)	1(20)				
Sex			P value > 0.05 ($P=0.162$)	1.737	0.018	0.175
Female	20(58.82)	1(20)				
Male	14(41.18)	4(80)				
Years of Working			P value > 0.05 ($P=0.388$)			
0-9	17(50)	4(80)				
9-15	7(20.59)	0				
15-29	10(29.41)	1(20)				
Occupation			P value > 0.05 ($P=0.343$)			
nurse	16(47.06)	4(80)				
paramedical staff	6(17.65)	0				
crew member	8(23.53)	0				
Physician	4(11.76)	1(20)				

¹⁾: Odds Ratio for Mupirocin (Resistance / sensitive), MuSSA, mupirocin susceptible *S.aureus*

Table 7: Antibiotic susceptibility pattern of MRSA and MSSA isolated from HCWs

Antibiotic	MSSA (N = 22), n (%)		MRSA (N = 17), n (%)	
	S	R	S	R
Amikacin	21(95.45)	1(4.55)	5(29.40)	12(70.60)
Ciprofloxacin	21(95.45)	1(4.55)	7(41.2)	10(58.80)
Erythromycin	21(95.45)	1(4.55)	2(11.80)	15(88.20)
Fusidic acid	22(100)	0	17(100)	0
Gentamicin	13(59.10)	9(40.9)	3(17.65)	14(82.35)
Linezolid	22(100)	0	17(100)	0
Mupirocin	22(100)	0	12(70.60)	5(29.40)
Oxacillin	22(100)	0	0	17(100)
Rifampin	22(100)	0	16(94.1)	1(5.9)
Tetracycline	20(90.90)	2(9.10)	3(17.65)	14(82.35)

Tobramycin	22(100)	0	15(88.2)	2(11.80)
Vancomycin	22(100)	0	17(100)	0

Discussion

S. aureus nasal colonization appears to play a significant role in the epidemiology and pathogenesis of infection (9). Mupirocin is a topical antibiotic agent that interferes with bacterial protein synthesis, which can be used for eradication of staphylococcal nasal colonization and control of MRSA transmission in Health Care Facilities (10). Today, the emergence of MuRSA strains has been reported from many parts of the world. The prevalence of these strains in Korea, India, South Africa and Nigeria has been reported 5%, 14.6%, 7% and 0.5 % respectively (11-14). Currently prevalence of mupirocin resistance in MRSA is increasing in areas where are widely used these antibiotics (15). There are scattered reports and limited number of study conducted to detect staphylococcal nasal colonization in Iran. In a study of hospitalized patients in Kermanshah, on nasal swabs, all isolates were susceptible to mupirocin that reflected the limited use of this antibiotic, especially in that region (16).

In present study the prevalence of *S. aureus* nasal colonization was 14.44% among which 17(43.58%) were MRSA and others were MSSA and 5 (1.85%) isolates found to be mupirocin-resistant. Of MuRSA isolates 3 were high level resistant. Prevalence of nasal carriage of *S. aureus* varied between hospitals and statistical information showed a significant relationship between the hospitals and presence of *S. aureus* nasal carrier as well. This seems to be due to differences in infection prevention and control measures. There were statistically significant relationship between nursing job and nasal carriage of *S. aureus* and MRSA but not with MuRSA carriage. This could be a warning because of the high possibility of nurse-to-patient transmission of these bacteria and dissemination of them in hospital setting. Therefore, practice of sanitary principles along with the routine screening of nasal carriers for the treatment purposes can be very useful in preventing the creation of epidemics in hospital setting.

None of the nasal carriers had a history of hospitalization or antibiotic use within the previous three months in our study. A significant relation was found between the sexes and nasal carriage of *S. aureus* ($P=0.035$) and MRSA ($P=0.041$) but not with MuRSA ($P=0.182$). This result is likely due to sample size or gender distribution of HCWs in the hospitals under studied. It is notable that we did not found any significant difference between age and years of working in hospital with regard to the nasal carriage of MSSA, MRSA and MuRSA.

In present study *mupA* gene PCR results were positive for two isolates and both of them were showed high-level resistance ($MIC>1024$) to mupirocin (isolates SH4, SH10). In addition, both of these two isolates were MRSA. Studies show that almost all of mupirocin resistant MRSA isolates with high resistance to mupirocin have positive PCR result for *mupA* gene (17, 18). Among these studies, there are some exceptions; this means that there are strains with high-level resistance to mupirocin, which are negative for the *mupA* gene. In these strains *mupA* gene, may located on chromosome rather than being on plasmids (19). This may justify and explain our result about strain S9. The results of our study indicated that one of the MRSA isolates (SH4) showed high level resistance to mupirocin by E-test method while was sensitive to mupirocin in disk diffusion method (this test was repeated 3 times), and it is noteworthy that this strain had positive PCR for *mupA* gene. Treatment with mupirocin in the presence of high-level resistance strains is not effective. In addition, there is evidence suggesting that presence of low-level resistant strains may cause failure in treatment (20-22). This emphasizes the importance of identification of both high and low level resistant strains.

So, due to some discrepancy in these two tests (disk diffusion test and E-test) it seems that the screening results obtained from disk diffusion method and MIC determination must be confirmed by other methods such as detection of resistance genes by PCR analysis in order to avoid false-

negative results. Hence, an unnecessary use of mupirocin and spread of resistant strains in hospital settings can be avoided by appropriate treatment decisions.

In this study, antibiotic susceptibility pattern of MRSA and MSSA strains were examined, that indicated antibiotic resistance among MRSA was much higher than MSSA. The highest resistance of MRSA isolates was related to erythromycin and all MSSA and MRSA strains were susceptible to linezolid, fusidic acid and vancomycin.

Conclusion

Since the HCWs play an important role as a reservoir for resistant isolates in the hospital setting, regularly screening should be performed for identification of nasal carriers. Consequently, because of antibiotic resistance among staphylococcal strains, thus antibiogram is a recommended method prior to treatment in order to select the best remedy.

Ethical considerations

Ethical issues (Including plagiarism, Informed Consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgement

This study was supported by Tehran University of Medical Sciences (Grant number 26590). The authors declare that there is no conflict of interests.

References

1. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG (2002). The evolutionary history of methicillin-resistant *Staphylococcus aureus* (MRSA). *Proc Natl Acad Sci US*, 99:7687-92.
2. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL (2005). The role of nasal carriage in *Staphylococcus aureus* infections. *Lancet Infect Dis*, 5: 751-62.
3. Patel JB, Gorwitz RJ, Jernigan JA (2009). Mupirocin Resistance. *Clin Infect Dis*, 49: 935-41.
4. Lari RA, Pourmand MR, Ohadian Moghadam S, Abdossamadi Z, Ebrahimzadeh Namvar A, Asghari B (2011). Prevalence of PVL-containing MRSA isolates among hospital staff nasal carriers. *Lab Med*, 42: 283-6.
5. Engelman R, Shahian D, Shemin R, Guy TS, Bratzler D, Edwards F, Jacobs M, Fernando H, Bridges C (2007). The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. *Ann Thorac Surg*, 83:1569-76.
6. Udo EE, Jacob LE, Mathew B (2001). Genetic analysis of methicillin-resistant *Staphylococcus aureus* expressing high and low-level mupirocin resistance. *J Med Microbiol*, 50: 909-15.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 21st Informational Supplement. 2011, CLSI document M100-S21. Wayne, Pennsylvania.
8. Braoios A, Fluminhan JA, Pizzolitto AC (2009). Multiplex PCR use for *Staphylococcus aureus* identification and oxacillin and mupirocin resistance evaluation. *Rev Ciênc Farm Básica Apl*, 30: 303-7.
9. Lakshmi S, Peerapur BV (2012). Study of nasal carriage of MRSA among the clinical staff and healthcare workers of a teaching hospital of Karnataka, India. *AlAmeen J Med Sci*, 5: 367-70.
10. Wertheim HF, Vos MC, Ott A, Voss A, Kluytmans JA, Vandenbroucke-Grauls CM, Meester MH, van Keulen PH, Verbrugh HA (2004). Mupirocin prophylaxis against nosocomial *Staphylococcus aureus* infections in nonsurgical patients, a randomized study. *Ann Intern Med*, 40: 419-25.
11. Yun HJ, Lee SW, Yoon GM, Kim SY, Choi S, Lee YS, Choi EC, Kim S (2003). Prevalence and mechanisms of low and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. *J Antimicrob Chemother*, 51: 619-23.
12. Gadepalli R, Dhawan B, Mohanty S, Kapil A, Das BK, Chaudhry R, Samantaray JC (2007). Mupirocin resistance in *Staphylococcus aureus* in an Indian hospital. *Diagn Microbiol Infect Dis*, 58: 125-7.

13. Shittu AO, Lin J (2006). Antimicrobial susceptibility patterns and characterization of clinical isolates of *Staphylococcus aureus* in KwaZulu-Natal province, South Africa. *BMC Infect Dis*, 6: 125-37.
14. Shittu AO, Lin J, Kolawole D (2006). Antimicrobial susceptibility patterns of *Staphylococcus aureus* and characterization of MRSA in Southwestern Nigeria. *WOUNDS*, 18: 77-84.
15. Simor AE, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin HR, Kiss A (2007). Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant *Staphylococcus aureus* colonization. *Clin Infect Dis*, 44: 178-85.
16. Mohajeri P, Gholamine B, Rezaei M, Khamisabadi Y (2012). Frequency of Mupirocin resistant *Staphylococcus aureus* strains isolated from nasal carriers in hospital patients in Kermanshah. *Jundishapur J Microb*, 5: 560-3.
17. Simor AE, Stuart TL, Louie L, Watt C, Ofner-Agostini M, Gravel D, Mulvey M, Loeb M, McGeer A, Bryce E, Matlow A (2007). Mupirocin-resistant, Methicillin-resistant *Staphylococcus aureus* strains in Canadian hospitals. *Antimicrob Agents Chemother*, 51: 3880-6.
18. Chaves F, García-Martínez J, de Miguel S, Otero JR (2004). Molecular characterization of resistance to mupirocin in methicillin-susceptible and -resistant isolates of *Staphylococcus aureus* from nasal samples. *J Clin Microbiol*, 42: 822-4.
19. Ramsey MA, Bradley SF, Kauffman CA, Morton TM (1996). Identification of chromosomal location of *mupA* gene, encoding low-level mupirocin resistance in staphylococcal isolates. *Antimicrob Agents Chemother*, 40: 2820-3.
20. Pourmand MR, Yousefi M, Salami SA, Amini M (2014). Evaluation of Expression of NorA Efflux Pump in Ciprofloxacin Resistant *Staphylococcus aureus* against Hexahydroquinoline Derivative by Real-Time PCR. *Acta Med Iran*, 52:424-9.
21. Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA (2003). Mupirocin-resistant, methicillin-resistant *Staphylococcus aureus*: does mupirocin remain effective? *Infect Control Hosp Epidemiol*, 24: 342-6.
22. Ohadian Moghadam S, Pourmand MR, Aminharati F (2014). Biofilm formation and antimicrobial resistance in methicillin-resistant *Staphylococcus aureus* isolated from burn patients, Iran. *J Infect Dev Ctries*, 8: 1511-7.